Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialPierre‐François Laterre, Anne-Aurore Duchambon, Peter Pickkers et al.|Intensive Care Medicine|2021Cited by 92
Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists WorkshopMattia Arrigo, Alexandre Mebazaa, Susanna Price et al.|The Lancet Respiratory Medicine|2021Cited by 52
Prognostic utility of a multi-biomarker panel in patients with suspected myocardial infarctionBetül Toprak, Franz–Josef Neumann, Tanja Zeller et al.|Clinical Research in Cardiology|2023Cited by 6
Prognostic utility of a multibiomarker panel in patients with suspected myocardial infarctionBetül Toprak, Franz–Josef Neumann, Jessica Weimann et al.|European Heart Journal|2022Cited by 1